All In Biotech

Free tool

FAERS Monitor: Gastrocrom

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020479 or its brand name (Gastrocrom, Cromolyn Sodium). Reports on generic versions are filed under their own applications.

Reports

3,311

Serious

1,201

36% of reports

Hospitalization

381

Death reported

38

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • treatment failure1,006
  • drug ineffective301
  • fatigue204
  • nausea193
  • headache168
  • off label use164
  • diarrhoea160
  • urticaria147
  • dyspnoea130
  • anaphylactic reaction127
  • pruritus124
  • pain122
  • hypersensitivity114
  • malaise110
  • condition aggravated109

Reports by year received

View as table
YearReports
200428
200524
200617
200720
200828
200944
201039
201145
201226
201316
201425
201540
201685
201765
201870
2019104
20201,101
2021139
2022212
2023256
2024317
2025346
2026264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,848 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
treatment failureSignal1,00678.174.175,838
anaphylactic reactionSignal12714.612.31,600
urticariaSignal1475.64.8552
hypersensitivitySignal1143.93.3245
condition aggravatedSignal1092.31.978
pruritusSignal1242.11.767
headache1681.71.549
fatigue2041.71.556
malaise1101.61.324
diarrhoea1601.61.434
nausea1931.51.438
dyspnoea1301.51.219
drug ineffective3011.51.345
pain1221.31.17
off label use1641.21.05

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.